Published in Ann Neurol on August 01, 1999
STIMEP : Assessment of Subthalamic Nucleus Stimulation in Drug Resistant Epilepsy | NCT00228371
Behavioural disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry (2002) 3.41
Neuropsychological outcomes from constant current deep brain stimulation for Parkinson's disease. Mov Disord (2016) 2.68
Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease. J Neurol Neurosurg Psychiatry (2004) 2.21
Relationship between neuropsychological outcome and DBS surgical trajectory and electrode location. J Neurol Sci (2009) 1.73
Cognitive outcome 5 years after bilateral chronic stimulation of subthalamic nucleus in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry (2006) 1.44
Bilateral subthalamic nucleus stimulation in advanced Parkinson's disease: five year follow-up. J Neurol (2009) 1.43
Does bilateral stimulation of the subthalamic nucleus aggravate apathy in Parkinson's disease? J Neurol Neurosurg Psychiatry (2005) 1.31
Sexual well being in parkinsonian patients after deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry (2004) 1.20
Neuropsychiatric effects of subthalamic neurostimulation in Parkinson disease. Nat Rev Neurol (2010) 1.17
Does subthalamic nucleus stimulation induce apathy in Parkinson's disease? J Neurol (2006) 1.10
Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson's disease. J Neurol Neurosurg Psychiatry (2006) 1.05
Cognitive and behavioural effects of chronic stimulation of the subthalamic nucleus in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry (2003) 1.03
Subthalamic nucleus deep brain stimulation in elderly patients--analysis of outcome and complications. BMC Neurol (2007) 0.99
Differential effects of subthalamic nucleus stimulation in advanced Parkinson disease on reaction time performance. Exp Brain Res (2005) 0.98
Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry (2006) 0.95
Subthalamic nucleus stimulation induces deficits in decoding emotional facial expressions in Parkinson's disease. J Neurol Neurosurg Psychiatry (2004) 0.95
Frontal cortex-like functions of the subthalamic nucleus. Front Syst Neurosci (2011) 0.95
Patient-specific analysis of the relationship between the volume of tissue activated during DBS and verbal fluency. Neuroimage (2010) 0.95
Effect of subthalamic stimulation on mood state in Parkinson's disease: evaluation of previous facts and problems. Neurosurg Rev (2005) 0.95
Dual channel deep brain stimulation system (Kinetra) for Parkinson's disease and essential tremor: a prospective multicentre open label clinical study. J Neurol Neurosurg Psychiatry (2002) 0.92
Deep brain stimulation and cognitive decline in Parkinson's disease: a clinical review. Front Neurol (2012) 0.92
Sociology of Low Expectations: Recalibration as Innovation Work in Biomedicine. Sci Technol Human Values (2015) 0.91
Intracranial electrode implantation produces regional neuroinflammation and memory deficits in rats. Exp Neurol (2009) 0.91
Bilateral subthalamic nucleus stimulation in advanced Parkinson's disease: three years follow-up. J Neurol (2007) 0.90
Influence of bilateral Stn-stimulation on psychiatric symptoms and psychosocial functioning in patients with Parkinson's disease. J Neural Transm (Vienna) (2005) 0.89
Long-term effects of STN DBS on mood: psychosocial profiles remain stable in a 3-year follow-up. BMC Neurol (2008) 0.86
Alcohol attentional bias: drinking salience or cognitive impairment? Psychopharmacology (Berl) (2006) 0.85
Apathy and verbal fluency in STN-stimulated PD patients. An observational follow-up study. J Neurol (2007) 0.85
Neuromodulation for obsessive-compulsive disorder. Neurotherapeutics (2014) 0.83
Defining a role for the subthalamic nucleus within operative theoretical models of subcortical participation in language. J Neurol Neurosurg Psychiatry (2003) 0.81
Reduced Verbal Fluency following Subthalamic Deep Brain Stimulation: A Frontal-Related Cognitive Deficit? PLoS One (2015) 0.81
Intact lexicon running slowly--prolonged response latencies in patients with subthalamic DBS and verbal fluency deficits. PLoS One (2013) 0.81
Deep brain stimulation for the treatment of Parkinson's disease: efficacy and safety. Degener Neurol Neuromuscul Dis (2012) 0.79
Do patient's get angrier following STN, GPi, and thalamic deep brain stimulation. Neuroimage (2010) 0.78
Impulsivities and Parkinson's disease: delay aversion is not worsened by Deep Brain Stimulation of the subthalamic nucleus. PLoS One (2012) 0.78
Neuropsychological effects of deep brain stimulation for Parkinson's disease. Surg Neurol Int (2013) 0.78
Unusual complications of deep brain stimulation. Neurosurg Rev (2014) 0.77
Motor and non motor effects during intraoperative subthalamic stimulation for Parkinson's disease. J Neurol (2005) 0.76
Impaired performance on the Wisconsin Card Sorting Test under left- when compared to right-sided deep brain stimulation of the subthalamic nucleus in patients with Parkinson's disease. J Neurol (2009) 0.76
Parkinson's Disease: Surgical Options. Curr Treat Options Neurol (2003) 0.76
Surgical management of Parkinson's disease: update and review. Interv Neuroradiol (2008) 0.76
Apathy and Reduced Speed of Processing Underlie Decline in Verbal Fluency following DBS. Behav Neurol (2017) 0.75
Improvement of Advanced Parkinson's Disease Manifestations with Deep Brain Stimulation of the Subthalamic Nucleus: A Single Institution Experience. Brain Sci (2016) 0.75
Worsening of Verbal Fluency After Deep Brain Stimulation in Parkinson's Disease: A Focused Review. Comput Struct Biotechnol J (2016) 0.75
High frequency deep brain stimulation of the subthalamic nucleus versus continuous subcutaneous apomorphine infusion therapy: a review. J Neural Transm (Vienna) (2010) 0.75
Effect of subthalamic deep brain stimulation on non-motor fluctuations in Parkinson's disease. J Neural Transm (Vienna) (2012) 0.75
The many facets of motor learning and their relevance for Parkinson's disease. Clin Neurophysiol (2017) 0.75
The FAB: a Frontal Assessment Battery at bedside. Neurology (2000) 8.93
Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology (1996) 8.82
Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med (1996) 6.57
Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med (2013) 6.37
Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ (1999) 5.36
Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet (2004) 5.06
Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med (2000) 4.98
Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med (1999) 4.79
Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med (1998) 4.72
Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain (2005) 4.33
The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain (1999) 4.25
Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet (1991) 3.89
Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol (1997) 3.80
Behavioural disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry (2002) 3.41
Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. J Neurosurg (1996) 3.37
Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet (1996) 3.26
Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl Neurophysiol (1987) 3.14
Predominant dystonia with marked cerebellar atrophy: a rare phenotype in familial dystonia. Neurology (2006) 3.07
Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet (1995) 3.06
Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial. Neurology (2006) 2.90
Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat Genet (1997) 2.77
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol (1994) 2.65
Neurosurgery in Parkinson disease: a distressed mind in a repaired body? Neurology (2006) 2.59
Environmental risk factors for REM sleep behavior disorder: a multicenter case-control study. Neurology (2012) 2.54
Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain (1991) 2.52
Cognitive deficits in Parkinson's disease. J Neurol (1997) 2.49
Partially overlapping neural networks for real and imagined hand movements. Cereb Cortex (2000) 2.47
Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol (2001) 2.45
Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem (1989) 2.44
Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat Genet (1995) 2.33
The mental representation of hand movements after parietal cortex damage. Science (1996) 2.28
Residual sleepiness in obstructive sleep apnoea: phenotype and related symptoms. Eur Respir J (2011) 2.28
Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem (1989) 2.26
The neural system that bridges reward and cognition in humans: an fMRI study. Proc Natl Acad Sci U S A (2002) 2.26
Bilateral subthalamic stimulation for Parkinson's disease by using three-dimensional stereotactic magnetic resonance imaging and electrophysiological guidance. J Neurosurg (2000) 2.25
Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease. Neurology (2004) 2.23
Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease. J Neurol Neurosurg Psychiatry (2004) 2.21
Frequency of the DYT1 mutation in primary torsion dystonia without family history. Arch Neurol (2000) 2.17
The impact on Parkinson's disease of electrical parameter settings in STN stimulation. Neurology (2002) 2.14
Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology (2012) 2.12
Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up. J Neurol Neurosurg Psychiatry (2005) 2.08
Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology (2000) 2.08
Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience (1996) 2.06
The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain (1999) 2.00
Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc Natl Acad Sci U S A (1997) 1.99
Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci U S A (2000) 1.97
X-linked Charcot-Marie-Tooth disease with connexin 32 mutations: clinical and electrophysiologic study. Neurology (1998) 1.96
Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson's disease. Brain (2009) 1.91
Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J Neurochem (1992) 1.91
Predictors of effective bilateral subthalamic nucleus stimulation for PD. Neurology (2002) 1.89
Mutations within the MGC4607 gene cause cerebral cavernous malformations. Am J Hum Genet (2004) 1.88
Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology (1997) 1.86
Neuropsychological changes between "off" and "on" STN or GPi stimulation in Parkinson's disease. Neurology (2000) 1.85
Relation of anosognosia to frontal lobe dysfunction in Alzheimer's disease. J Neurol Neurosurg Psychiatry (1994) 1.85
Parkinson's disease and sleepiness: an integral part of PD. Neurology (2002) 1.85
Eye movements in parkinsonian syndromes. Ann Neurol (1994) 1.84
MRI-guided STN DBS in Parkinson's disease without microelectrode recording: efficacy and safety. J Neurol Neurosurg Psychiatry (2010) 1.84
Cortical control of reflexive visually-guided saccades. Brain (1991) 1.84
Amygdalohippocampal MR volume measurements in the early stages of Alzheimer disease. AJNR Am J Neuroradiol (1994) 1.81
Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol (1998) 1.80
Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features. Ann Neurol (1996) 1.77
Human autonomy and the frontal lobes. Part I: Imitation and utilization behavior: a neuropsychological study of 75 patients. Ann Neurol (1986) 1.77
The impact of deep brain stimulation on executive function in Parkinson's disease. Brain (2000) 1.74
A multidisciplinary study of patients with early-onset PD with and without parkin mutations. Neurology (2008) 1.74
Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett (1994) 1.73
Severe tongue protrusion dystonia: clinical syndromes and possible treatment. Neurology (2006) 1.72
Distribution of grey matter atrophy in Huntington's disease patients: a combined ROI-based and voxel-based morphometric study. Neuroimage (2006) 1.72
Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions? Neurology (1987) 1.70
Pallidal stimulation for Parkinson's disease. Two targets? Neurology (1997) 1.69
Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res (1983) 1.67
Acute and long-term effects of subthalamic nucleus stimulation in Parkinson's disease. Stereotact Funct Neurosurg (1994) 1.66
Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions. Hum Mol Genet (1998) 1.64
Tourette's syndrome and deep brain stimulation. J Neurol Neurosurg Psychiatry (2005) 1.60